Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 30, 2016. The document serves as a transaction notification regarding the grant of share options to Persons Discharging Managerial Responsibilities (PDMRs) under the Company's ShareSave Plan 2016.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to specific executive compensation transactions and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details the execution of equity incentive grants on November 30, 2016.
Management Commentary and Transaction Details
The filing discloses the grant of options over Ordinary Shares (ISIN: GB0009252882) to three executives at an exercise price of £12.95 per share. The transactions were conducted on the London Stock Exchange (XLON).
- Mr. S. Dingemans (Chief Financial Officer): Granted 208 options.
- Mr. S. A. Hussain (President, Global Pharmaceuticals): Granted 694 options.
- Mr. P. C. Thomson (SVP, Communications & Government Affairs): Granted 277 options.
Investor Verification Checklist
- Verify the total number of options granted to PDMRs under the ShareSave Plan 2016.
- Confirm the exercise price of £12.95 aligns with the market price on the grant date.
- Review the full ShareSave Plan 2016 terms for vesting schedules and performance conditions not detailed in this summary.
- Check subsequent filings for the actual exercise or expiration of these specific options.